Stephen Anthony Strickland Jr. MD MD, MSCI

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Director of Leukemia Research at Sarah Cannon Research Institute

2410 Patterson StreetSuite 500Nashville, TN 37203
Phone+1 615-342-7440

Dr. Strickland is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Strickland's full profile Already have an account?

Education & Training

Vanderbilt University School of MedicineMaster of Science in Clinical Investigation, 2007 - 2010
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Vanderbilt University Medical CenterResidency, Internal Medicine, 2002 - 2005
Louisiana State University School of Medicine in New OrleansClass of 2002, MD
Barry UniversityMS, Biomedical Sciences, 1995 - 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

TN State Medical License 2005 - 2027
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification StarPanel, Vanderbilt University, 2012, 2014-2015
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2008 Oct 01
COMPLETED
PHASE1
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies Start of enrollment: 2010 May 11
COMPLETED
PHASE1, PHASE2
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
COMPLETED
PHASE1

Publications & Presentations

PubMed

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy.
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov
Blood Advances. 2026-02-24
Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial.
Giovanni Martinelli, Scott R Solomon, Sudipto Mukherjee, Armando Santoro, Stephen A Strickland
Blood Neoplasia. 2026-02-01
1 citations
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141).
Robert Jeraj, Fenghai Duan, Ryan J Mattison, Justin Romanoff, Lale Kostakoglu
Leukemia & Lymphoma. 2025-12-01

Abstracts/Posters

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylatin...
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase...
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Anal...
Stephen A. Strickland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Sarah Cannon Research Institute to Present Research on Advances in Blood Cancers and Blood Disorders at 2025 ASH Annual Meeting & ExpositionDecember 8th, 2024